Novavax Financial Ratios
NASDAQ: NVAXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
12.75+1.74 (+15.80%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Novavax ratio analysis
Novavax earned a net margin of 39.2% in FY 2025, up from -27.5% a year earlier. Gross margin was 93.5% compared with a median of 70.3% over the prior 5 years. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Novavax financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 2.76 | — | — | — | — | — | — | — | — | — |
| Price / sales | 1.03 | 1.97 | 0.49 | 0.41 | 9.29 | 13.49 | 5.73 | 23.08 | 11.64 | 444.49 |
| Price / book | — | — | — | — | — | 10.23 | — | — | — | — |
| Gross margin | 93.5% | 70.3% | 65.1% | 54.5% | 100.0% | 100.0% | — | — | — | — |
| Operating margin | 40.3% | -36.5% | -57.6% | -32.5% | -147.1% | -87.6% | -646.1% | -507.2% | -550.8% | -1,752.8% |
| Net margin | 39.2% | -27.5% | -55.4% | -33.2% | -152.1% | -87.9% | -711.0% | -538.8% | -589.5% | -1,823.5% |
| Free cash flow margin | -22.3% | -14.7% | -78.0% | -25.5% | 23.2% | -20.4% | -742.0% | -543.0% | -476.9% | -1,804.0% |
| Return on equity (ROE) | — | — | — | — | — | -66.7% | — | — | — | — |
| Return on assets (ROA) | 37.4% | -12.0% | -30.3% | -29.1% | -67.7% | -26.4% | -76.7% | -88.8% | -60.8% | -71.0% |
| Current ratio | 2.13 | 0.98 | 0.70 | 0.69 | 0.90 | 2.15 | 3.77 | 2.62 | 2.76 | 4.33 |
| Revenue growth | 64.7% | -30.7% | -50.4% | 72.9% | 141.0% | 2,448.5% | -45.6% | 10.0% | 103.1% | -57.6% |